In Drug Price Debate, Pharma Turns Focus To Coverage, But Insurers Want Price Transparency
At a conference on drug pricing, PhRMA CEO Castellani says the focus should be on making sure insurers are not discouraging use through high cost-sharing, while AHIP CEO Ignagni says the components of drug prices need to be transparent.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.